The antibiotic reality The antibiotic market is a >$30 billion market worldwide The antibiotic pipeline is as empty as it has been since the discovery of antibiotics (97% of antibiotics in development are analogs of existing drugs) Antibiotic resistance has emerged as a major challenge in public and personal health The search for single “blockbuster” broad-spectrum antibiotics is both medically and ecologically foolish

The antibiotic crisis: MRSA

Origin is committed to the design of effective The new antibiotic landscape The search for single “blockbuster” broad-spectrum antibiotics is medically, ecologically and financially untenable. Origin is committed to the design of effective narrow spectrum antimicrobials that: Specifically target pathogenic organisms Reduce the emergence of resistance Leverage developments in diagnostics and personalized medicine

Bacteriocin Diversity Bacteriocins May be universally present in Bacteria, certainly prevalent E. coli - colicins P. aeruginosa - pyocin B. subtilis - subtilin S. epidermis - epidermin L. brevis - brevicin Archaeacins Universally present

“…pitted against microbial genes we have mainly our wits “…pitted against microbial genes we have mainly our wits.” Joshua Lederberg Our leads derive from a family of naturally-occurring antimicrobials, the bacteriocins Ubiquitous Specific and targetable Nontoxic to vertebrates Modifiable and patentable Ia E9

3 billion years of R&D Conventional antibiotics Dr. Robert Dorit or Dr. Margaret Riley For additional information, contact: origin.antimicrobials@gmail.com Yr 15-20 Discovery Preclinical Animal Trials Phase I Phase II Phase III FDA Post Market Yr 0 Yr 7 Conventional antibiotics Discovery Preclinical Animal Trials Phase I Phase II Phase III FDA Post Market Yr 0 Yr 2 The lead to bedside pipeline